Asset Details
Do you wish to reserve the book?
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Do you wish to request the book?
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
2013
Overview
Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients.
Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide.
1
,
2
Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
3
–
7
Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . .
Publisher
Massachusetts Medical Society
Subject
/ Androstadienes - adverse effects
/ Androstadienes - therapeutic use
/ Antineoplastic Agents, Hormonal - adverse effects
/ Antineoplastic Agents, Hormonal - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Humans
/ Male
/ Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
/ Nephrology. Urinary tract diseases
/ Prednisone - adverse effects
/ Prednisone - therapeutic use
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - secondary
/ Tumors
